Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667117 · ClinicalTrials.gov registry record · Phase 4
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT04667117 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT04667117, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.
Interventions
- DRUG Ofatumumab
- BIOLOGICAL Quadrivalent influenza vaccine
- DRUG iDMT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04667117
The ClinicalTrials.gov registry entry for NCT04667117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ofatumumab is the first listed.
NCT04667117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04667117 about?
NCT04667117 is a clinical study titled "A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.
What is the current status of trial NCT04667117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2021-01-14. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT04667117?
The interventions under investigation include: Ofatumumab (DRUG), Quadrivalent influenza vaccine (BIOLOGICAL), iDMT (DRUG).
Who is sponsoring clinical trial NCT04667117?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.